Exocrine pancreatic inflammation in canine diabetes mellitus - An active offender?

Exocrine pancreatic inflammation may actively contribute to canine diabetes through β-cell loss.

This review examines the relationship between exocrine pancreatic inflammation and canine diabetes mellitus, proposing that exocrine pancreatic disease may be an underrecognized contributor to β-cell loss and insulin-deficiency diabetes in dogs. Post-mortem studies reveal concurrent pancreatitis in approximately 30% of diabetic canine patients, suggesting a potential pathogenic link. The authors highlight significant clinical challenges: current diagnostic methods for pancreatitis lack precision, making early detection difficult, and existing treatment approaches are suboptimal. Diabetes management relies on daily insulin injections, creating welfare and financial burdens for owners, while pancreatitis treatment focuses on symptomatic relief rather than addressing underlying etiology. The review synthesizes current evidence supporting exocrine pancreatic inflammation as an active contributor to pancreatic β-cell dysfunction and explores both established and emerging diagnostic and therapeutic strategies. Understanding this interplay is crucial for veterinarians to improve outcomes in dogs with concurrent or sequential pancreatic disease, potentially preventing or delaying diabetes development through targeted pancreatitis intervention.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.